Zika Envelope Domain-3
Description
Product Specs
For long-term storage, keep the lyophilized Zika Envelope protein at a temperature between 2-8°C. Avoid freezing. After reconstitution, the Zika Envelope protein should be stored at 4°C for up to 6 months. For longer storage periods, it can be stored at -18°C.
Repeated freezing and thawing of the protein should be avoided.
Product Science Overview
The Zika virus (ZIKV) is a mosquito-borne flavivirus that belongs to the family Flaviviridae. It is closely related to other flaviviruses such as dengue virus (DENV), West Nile virus (WNV), and yellow fever virus (YFV). ZIKV has gained significant attention due to its association with severe clinical conditions, including Guillain-Barré syndrome and congenital microcephaly .
The envelope (E) protein of ZIKV is a critical component of the virus’s structure and function. It consists of three ectodomains: EDI, EDII, and EDIII. The E protein facilitates viral invasion by mediating receptor binding, cellular attachment, viral entry, and fusion . Among these domains, the envelope domain III (EDIII) is particularly important as it is a major target for neutralizing antibodies .
Recombinant Zika Envelope Domain-III (rZE3) is a synthetically produced version of the EDIII of the Zika virus envelope protein. This recombinant protein is typically produced using an Escherichia coli (E. coli) expression system . The recombinant form of EDIII is designed to mimic the natural structure of the viral protein, making it a valuable tool for research and vaccine development.
The immunogenicity of rZE3 has been extensively studied to evaluate its potential as a vaccine candidate against ZIKV. Research has shown that immunization with rZE3 can induce the production of ZIKV-specific neutralizing antibodies . These antibodies play a crucial role in providing protection against ZIKV infection by neutralizing the virus and preventing it from infecting host cells.
In addition to its immunogenic properties, rZE3 has been shown to activate dendritic cells, which are essential for initiating and regulating immune responses . Studies have demonstrated that immunization with rZE3 can lead to the production of effector cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-12 (IL-12), further enhancing the immune response .
The recombinant lipidated form of Zika Envelope Domain-III (rLZE3) has shown promise as a vaccine candidate. This lipidated version possesses intrinsic adjuvant properties, which enhance its immunogenicity without the need for additional adjuvants . Immunization with rLZE3 has been shown to induce durable neutralizing antibody responses and provide protection against ZIKV challenge in animal models .
